Cisplatin (CDDP) is one among the most effective and widely used anticancer drugs. Its use is, however, often limited by its peripheral neurotoxicity, which may be severely disabling and sometimes not reversible. To prevent or reduce CDDP peripheral neurotoxicity several "neuroprotective" drugs have been proposed. This goal is of extreme importance in the treatment of cancer patients, especially in view of the better results obtained by anticancer chemotherapy in terms of longer disease-free survival which has made even more crucial than in the past the point of the quality of life of the long-surviving patients. The data of pre-clinical and clinical studies with neuroprotectant agents are often conflicting, in some cases because of inadequate methods of evaluation and/or study design used to examine their effectiveness. The aims of this review will be 1) to discuss and describe the most appropriate methods of evaluation of CDDP and neuro-protectant drugs in experimental in vitro and in vivo pre-clinical studies 2) to evaluate critically the results of the clinical trials reported so far with the combined treatment and 3) to explore the possible future strategies to achieve neuroprotection during high-dose CDDP treatment in humans

Cavaletti, G., Cascinu, S., Venturino, P., Tedeschi, M., Tredici, G. (1996). Neuroprotectant drugs in cisplatin neurotoxicity. ANTICANCER RESEARCH, 16(5B), 3149-3159.

Neuroprotectant drugs in cisplatin neurotoxicity

CAVALETTI, GUIDO ANGELO;TREDICI, GIOVANNI
1996

Abstract

Cisplatin (CDDP) is one among the most effective and widely used anticancer drugs. Its use is, however, often limited by its peripheral neurotoxicity, which may be severely disabling and sometimes not reversible. To prevent or reduce CDDP peripheral neurotoxicity several "neuroprotective" drugs have been proposed. This goal is of extreme importance in the treatment of cancer patients, especially in view of the better results obtained by anticancer chemotherapy in terms of longer disease-free survival which has made even more crucial than in the past the point of the quality of life of the long-surviving patients. The data of pre-clinical and clinical studies with neuroprotectant agents are often conflicting, in some cases because of inadequate methods of evaluation and/or study design used to examine their effectiveness. The aims of this review will be 1) to discuss and describe the most appropriate methods of evaluation of CDDP and neuro-protectant drugs in experimental in vitro and in vivo pre-clinical studies 2) to evaluate critically the results of the clinical trials reported so far with the combined treatment and 3) to explore the possible future strategies to achieve neuroprotection during high-dose CDDP treatment in humans
Recensione in rivista
Animals; Sulfhydryl Compounds; Cisplatin; Antineoplastic Agents; Humans; Clinical Trials as Topic; Calcium Channel Blockers; Nervous System; Nerve Growth Factors; Nerve Tissue Proteins; Adrenocorticotropic Hormone
English
set-1996
16
5B
3149
3159
none
Cavaletti, G., Cascinu, S., Venturino, P., Tedeschi, M., Tredici, G. (1996). Neuroprotectant drugs in cisplatin neurotoxicity. ANTICANCER RESEARCH, 16(5B), 3149-3159.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/44787
Citazioni
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
Social impact